1
|
van Balveren JA, Verboeket-van de Venne WPHG, Erdem-Eraslan L, de Graaf AJ, Loot AE, Musson REA, Oosterhuis WP, Schuijt MP, van der Sijs H, Verheul RJ, de Wolf HK, Kusters R, Hoedemakers RMJ. Diagnostic error as a result of drug-laboratory test interactions. Diagnosis (Berl) 2019; 6:69-71. [PMID: 30753158 DOI: 10.1515/dx-2018-0098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Accepted: 01/28/2019] [Indexed: 11/15/2022]
Abstract
Background Knowledge of possible drug-laboratory test interactions (DLTIs) is important for the interpretation of laboratory test results. Test results may be affected by physiological or analytical drug effects. Failure to recognize these interactions may lead to misinterpretation of test results, a delayed or erroneous diagnosis or unnecessary extra tests or therapy, which may harm patients. Content Thousands of interactions have been reported in the literature, but are often fragmentarily described and some papers even reported contradictory findings. How can healthcare professionals become aware of all these possible interactions in their individual patients? DLTI decision support applications could be a good solution. In a literature search, only four relevant studies have been found on DLTI decision support applications in clinical practice. These studies show a potential benefit of automated DLTI messages to physicians for the interpretation of laboratory test results. All physicians reported that part of the DLTI messages were useful. In one study, 74% of physicians even sometimes refrained from further additional examination. Summary and outlook Unrecognized DLTIs potentially cause diagnostic errors in a large number of patients. Therefore, efforts to avoid these errors, for example with a DLTI decision support application, could tremendously improve patient outcome.
Collapse
Affiliation(s)
- Jasmijn A van Balveren
- Laboratory for Clinical Chemistry and Haematology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.,Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | | | - Lale Erdem-Eraslan
- Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - Albert J de Graaf
- Department of Clinical Chemistry, Medical Spectrum Twente, Enschede, The Netherlands
| | | | - Ruben E A Musson
- Laboratory for Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Wytze P Oosterhuis
- Department of Clinical Chemistry, Zuyderland Medical Centre, Heerlen, The Netherlands
| | - Martin P Schuijt
- Department of Clinical Chemistry, Slingeland Hospital, Doetinchem, The Netherlands
| | - Heleen van der Sijs
- Department of Hospital Pharmacy, Erasmus Medical Centre, University Medical Centre Rotterdam, Rotterdam, The Netherlands
| | - Rolf J Verheul
- Department of Clinical Chemistry, LabWest/HMC Westeinde, The Hague, The Netherlands
| | - Holger K de Wolf
- Department of Clinical Chemistry, Rivierenland Hospital, Tiel, The Netherlands
| | - Ron Kusters
- Laboratory for Clinical Chemistry and Haematology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.,Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| | - Rein M J Hoedemakers
- Laboratory for Clinical Chemistry and Haematology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands
| | | |
Collapse
|